Who
Samarth Kulkarni
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, CRISPR Therapeutics AG; Director, Black Diamond Therapeutics; Director, Centessa Pharmaceuticals; Director, Oruka Therapeutics; Director, Repare Therapeutics.
In numbers
- Trades disclosed
- 352
- Buys
- 0
- Sells
- 60
- Bought
- $0
- Sold
- $74.6M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 19 Apr 2017
- Last trade
- 19 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 20 Oct 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $2.4M47,837 at $49.78 | filing |
| 16 Oct 2026filed 20 Oct 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —100,000 | filing |
| 16 Oct 2026filed 20 Oct 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —100,000 | filing |
| 14 Oct 2026filed 15 Oct 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $202K4,098 at $49.26 | filing |
| 13 Oct 2026filed 15 Oct 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —8,333 | filing |
| 13 Oct 2026filed 15 Oct 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —8,333 | filing |
| 26 Jun 2026filed 29 Jun 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —208,474 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —208,474 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 2 Jun 2026filed 3 Jun 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,136 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,136 at $0.00 | filing |
News
CRISPR Therapeutics Announces Chief Financial Officer TransitionCRSP · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026
0 headlines in the last 90 days name Samarth Kulkarni; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.